Has The Street Misdiagnosed Immunex?By
Although Immunex thinks it scored a giant victory in March when the Food & Drug Administration approved the marketing of its first product, GM-CSF, investors didn't quite see it that way. Immunex's stock began to head south--slumping from 59 to 43 on July 9. Some big players worry that the new bio-engineered drug, trademarked as Leukine, won't be able to compete with a widely used Amgen product. But not everyone shares their concern: Investment manager Bill Harnisch has been buying, building up a 12% stake in Immunex recently.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.